ClinicalTrials.Veeva

Menu

tDCS Coupled With Virtual Rehabilitation for Negative Symptoms in At-Risk Youth

C

Center for Addiction and Mental Health (CAMH)

Status

Unknown

Conditions

Clinical High Risk for Psychosis

Treatments

Device: Sham tDCS
Behavioral: Active VR Motivation Training
Device: Active tDCS
Behavioral: Sham VR Motivation Training

Study type

Interventional

Funder types

Other

Identifiers

NCT02951208
039-2016

Details and patient eligibility

About

Negative symptoms, which include the loss of motivation, social withdrawal and reduced emotional expression are prominent in youth at clinical high risk (CHR) for psychosis. These negative symptoms lead to significant functional impairment and enduring disability in these youth. At present, there are no established treatments for negative symptoms. Recent evidence from independent studies, however, suggests two promising novel treatment approaches for negative symptoms, transcranial direct current stimulation (tDCS), and computerized remediation strategies. The primary aim of this study is to evaluate if tDCS combined with a virtual reality-based computerized remediation (VR) is effective for treating negative symptoms in CHR youth, thereby mitigating the enduring functional disability these symptoms cause.

Full description

Negative symptoms, which include amotivation, social withdrawal and diminished emotional expression are prominent in youth at clinical high risk (CHR) for psychosis. Negative symptoms lead to significant functional impairment and enduring disability in these youth regardless of subsequent conversion to psychosis. At present, there are no established treatments for negative symptoms. Recent evidence from independent studies, however, suggests two promising novel treatment approaches for negative symptoms, transcranial direct current stimulation (tDCS), and computerized remediation strategies, both of which have revealed significant therapeutic effects on negative symptoms in schizophrenia (SZ). tDCS involves delivery of a low intensity continuous electrical field to the frontal cortex. tDCS is very safe and well tolerated, and is currently being investigated as a treatment for several psychiatric disorders. tDCS is also Health Canada approved for the treatment of major depressive disorder. The primary aim of this randomized controlled trial is to evaluate if tDCS combined with a virtual reality-based computerized remediation (VR), administered three times per week for four weeks, is effective for treating negative symptoms in CHR youth, thereby mitigating the enduring functional disability these symptoms cause.

Enrollment

22 estimated patients

Sex

All

Ages

16 to 30 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. between the ages of 16 and 30;
  2. meet CHR criteria for a psychosis risk syndrome determined by the Structured Interview for Prodromal Symptoms (SIPS);
  3. have a Scale of Prodromal Symptoms (SOPS) negative subscale (SOPS-Neg) score of > 11, with at least one negative symptom of at least moderate severity (i.e., ≥ 3)

Exclusion criteria

  1. meet criteria for a current or lifetime psychotic disorder;
  2. have an IQ < 70;
  3. a history of seizures or clinically significant neurological disorder that may contribute to prodromal symptoms.
  4. have been involved in another treatment study in the past 4 weeks.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

22 participants in 2 patient groups

Active tDCS + Active VR
Experimental group
Description:
Active tDCS over the left DLPFC (30 minutes) combined with active VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
Treatment:
Device: Active tDCS
Behavioral: Active VR Motivation Training
Sham tDCS + Sham VR
Sham Comparator group
Description:
Sham tDCS over the left DLPFC (30 minutes) combined with sham VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
Treatment:
Device: Sham tDCS
Behavioral: Sham VR Motivation Training

Trial contacts and locations

1

Loading...

Central trial contact

George Foussias, MD PhD FRCPC; Jessica D'Arcey

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems